Monte Rosa investors back board slate, auditor

Monte Rosa Therapeutics held its 2026 annual stockholder meeting, where investors voted on board elections and the company’s auditor.

Rhea-AI Filing Summary

Monte Rosa Therapeutics held its 2026 annual stockholder meeting, where investors voted on board elections and the company’s auditor. As of the April 16, 2026 record date, there were 84,382,573 shares of common stock outstanding.

Stockholders elected three Class II directors to serve until the 2029 annual meeting. Andrew Schiff, M.D. received 71,409,008 votes for and 741,197 withheld; Chandra P. Leo, M.D. received 71,469,933 votes for and 680,272 withheld; and Anthony Manning, Ph.D. received 56,995,916 votes for and 15,154,289 withheld. Each director election also had 3,128,885 broker non-votes.

Stockholders also ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 75,171,524 votes for, 57,950 against, 49,616 abstentions and no broker non-votes. No other matters were submitted for a vote at the meeting.

8-K Event Classification

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Key Figures

Shares outstanding record date: 84,382,573 shares Votes for Andrew Schiff, M.D.: 71,409,008 votes Votes for Chandra P. Leo, M.D.: 71,469,933 votes +5 more

8 metrics

Shares outstanding record date 84,382,573 shares Common stock outstanding as of April 16, 2026

Votes for Andrew Schiff, M.D. 71,409,008 votes Election as Class II director at 2026 annual meeting

Votes for Chandra P. Leo, M.D. 71,469,933 votes Election as Class II director at 2026 annual meeting

Votes for Anthony Manning, Ph.D. 56,995,916 votes Election as Class II director at 2026 annual meeting

Broker non-votes director items 3,128,885 votes Broker non-votes for each Class II director election

Votes for Deloitte & Touche LLP 75,171,524 votes Ratification as independent registered public accounting firm for 2026

Votes against Deloitte & Touche LLP 57,950 votes Ratification of independent registered public accounting firm for 2026

Abstentions on auditor ratification 49,616 votes Ratification of Deloitte & Touche LLP for fiscal year ending December 31, 2026

Key Terms

Annual Meeting of Stockholders, Class II directors, independent registered public accounting firm, broker non-votes, +1 more

5 terms

Annual Meeting of Stockholders regulatory

"Monte Rosa Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders"

Class II directors regulatory

"elect three directors ... as Class II directors of the Company"

independent registered public accounting firm regulatory

"ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm"

An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.

broker non-votes financial

"The results of the stockholders’ vote ... included broker non-votes"

Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

record date financial

"As of April 16, 2026, the record date for the Annual Meeting"

The record date is the specific day when a company determines which shareholders are eligible to receive a dividend or participate in an upcoming vote. It’s like a cutoff date; if you own the stock on that day, you get the benefits or voting rights. This date matters because it decides who qualifies for certain company benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Monte Rosa Therapeutics (GLUE) vote on at the 2026 annual meeting?

Stockholders voted on electing three Class II directors and ratifying Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. No other matters were submitted for a vote at the meeting.

How many Monte Rosa Therapeutics (GLUE) shares were eligible to vote at the 2026 meeting?

As of the April 16, 2026 record date, 84,382,573 shares of Monte Rosa Therapeutics common stock were outstanding and entitled to vote. This figure defines the maximum potential voting power for the 2026 Annual Meeting of Stockholders described in the disclosure.

Were Monte Rosa Therapeutics’ 2026 director nominees elected by stockholders?

Yes. Stockholders elected Andrew Schiff, M.D., Chandra P. Leo, M.D. and Anthony Manning, Ph.D. as Class II directors for terms ending at the 2029 annual meeting, each continuing until a successor is elected and qualified or earlier resignation or removal according to the company’s governance framework.

How strong was support for Deloitte & Touche as Monte Rosa Therapeutics’ auditor for 2026?

Stockholders ratified Deloitte & Touche LLP with 75,171,524 votes for, 57,950 against and 49,616 abstentions, with zero broker non-votes. This outcome confirms Deloitte & Touche LLP as Monte Rosa’s independent registered public accounting firm for the 2026 fiscal year.

What were the vote totals for Monte Rosa director Anthony Manning, Ph.D. in 2026?

Anthony Manning, Ph.D. received 56,995,916 votes for and 15,154,289 votes withheld, with 3,128,885 broker non-votes. Despite a higher number of withheld votes than other nominees, he was elected to a Class II director term ending at the 2029 annual meeting.

Did Monte Rosa Therapeutics (GLUE) consider any other proposals at the 2026 annual meeting?

No. The only matters presented were the election of the three Class II director nominees and the ratification of Deloitte & Touche LLP as the independent registered public accounting firm. The company states that no other matters were submitted or voted upon.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/11/2026 - 04:01 PM EDT Learn about SEC filing dates

0001826457false00018264572026-06-112026-06-11

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 11, 2026

MONTE ROSA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-40522		84-3766197
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

321 Harrison Avenue, Suite 900

Boston, MA 02118

(Address of principal executive offices, including zip code)

(617) 949-2643

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		GLUE		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07. Submission of Matters to Vote of Security Holders

On June 11, 2026, Monte Rosa Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). As of April 16, 2026, the record date for the Annual Meeting, there were 84,382,573 outstanding shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”). The Company’s stockholders voted on the following matters, which are described in detail in the Company’s definitive proxy statement on Schedule 14A (the “Proxy Statement”): (i) to elect three directors, Andrew Schiff, M.D., Chandra P. Leo, M.D. and Anthony Manning, Ph.D., as Class II directors of the Company, each to serve for a three-year term expiring at the Company’s 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, subject to their earlier death, resignation or removal and (ii) to ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

Proposal 1 - Election of Class II Director Nominees

The stockholders of the Company elected Andrew Schiff, M.D., Chandra P. Leo, M.D. and Anthony Manning, Ph.D. as Class II directors of the Company, for a three-year term ending at the annual meeting of stockholders to be held in 2029 and until their successors have been duly elected and qualified or until their earlier resignation or removal. The results of the stockholders’ vote with respect to the election of the Class II directors were as follows:

		Votes For		Votes Withheld		Broker Non-Votes
Andrew Schiff, M.D.		71,409,008		741,197		3,128,885
Chandra P. Leo, M.D.		71,469,933		680,272		3,128,885
Anthony Manning, Ph.D.		56,995,916		15,154,289		3,128,885

Proposal 2 - Ratification of Appointment of the Company’s Independent Registered Public Accounting Firm

The stockholders of the Company ratified the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of the stockholders’ vote with respect to such ratification were as follows:

Votes		Votes				Broker
For		Against		Abstain		Non-Votes
75,171,524		57,950		49,616		0

No other matters were submitted to or voted on by the Company’s stockholders at the Annual Meeting.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				Monte Rosa Therapeutics, Inc.
Date: June 11, 2026				By:		/s/ Markus Warmuth
						Markus Warmuth
						President and Chief Executive Officer

Filing Exhibits & Attachments

1 document

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 30.0 KB